WRWilliam Rosenberg

William Rosenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William Rosenberg has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • J. Parkes

    Univ Southampton, Primary Care & Populat Sci, Fac Med, Southampton, Hants, England

    20 shared publications
  • Julie Parkes

    Primary Care, Public Health and Medical Statistics, University of Southampton, Southampton, UK

    20 shared publications
  • S. Tanwar

    UCL, Inst Liver & Digest Hlth, Div Med, Royal Free Hosp, London, England

    16 shared publications
  • Sudeep Tanwar

    Institute for Liver and Digestive Health, Division of Medicine, University College London, Hampstead, London, UK

    16 shared publications
  • Paul Roderick

    Academic Unit of Primary Care and Population Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

    14 shared publications
  • Ankur Srivastava

    Division of Medicine & Royal Free London NHS Foundation Trust, Institute for Liver and Digestive Health University College London London UK

    12 shared publications

Latest Publications

  • Open Access

    Evaluation of Liver Fibrosis Change After DAA-induced Cure of Hepatitis C in Participants With and Without HIV: ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (VHICS)

    by Marion G Peters, Minhee Kang, Robert Murphy, William Rosenberg, David L Wyles

    Change in liver fibrosis was studied over 5 years after cure of hepatitis C (HCV) in participants with and without HIV from the Viral Hepatitis C Infection Long-Term Cohort Study (VHICS). Markers of liver fibrosis included aspartate aminotransferase to platelet ratio (APRI), fibrosis 4 index (FIB-4), and a direct measure of extracellular matrix, enhanced liver fibrosis (ELF). We evaluated 122 participants without HIV and 128 with HIV. At study entry, which occurred on average 30 weeks after antiviral completion, more participants had severe fibrosis by ELF (21%) than FIB-4 (7%) or APRI (1%). ELF scores were not available before entry into VHICS. The proportions of participants in predefined ELF categories were similar between the 2 groups at study entry and over time. Advanced fibrosis by ELF did not decrease over time. Clinical events were observed in 44 (12%): 29 HCV/HIV and 15 HCV participants. HCV/HIV participants had a 1.95 times higher risk of developing a clinical event, compared to HCV. A lower entry ELF score was numerically associated with a lower risk of a clinical event. There was an association between VHICS entry ELF and time to first targeted liver diagnosis or all-cause death (hazard ratio; 95% CI, 0.268 [.094-.763], P = .014). In conclusion, APRI and FIB-4 decreases occurred early after direct-acting antiretroviral therapy, likely from decreased necroinflammation. ELF identified participants who continued to have advanced liver fibrosis and was associated with development of liver outcomes and death. Studies after sustained virologic response should include longer term follow up to monitor for clinical events.

  • Open Access

    The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT): Use of a Clinical Database Case‐Finding Tool for Hepatitis B, Hepatitis C and HIV in Primary Care

    by David Etoori, Sara Cococcia, Ankur Srivastava, Stuart Flanagan, Grainne Nixon, Satya Bobba, Alex Warner, Karen Sennett, Caroline Sabin, Sarah Morgan, et al.

    Despite the availability of effective treatment and vaccines for hepatitis B virus (HBV) and C virus (HCV), many people are still infected and remain unaware of their infection. The Camden and Islington Viral Hepatitis Identification Tool (CIVHIT), a computer‐based search tool, was introduced in 60 general practices (GPs) in April 2014 to support identification, testing and treatment of individuals at high risk for blood‐borne viruses (BBVs). CIVHIT searched electronic medical records (EMRs), flagging all those with codes linked to risk factors or medical conditions associated with BBVs. CIVHIT was associated with a 78.5% increase in BBV tests in primary care in both boroughs. This translated to a 55.8% rise in new diagnoses. HBV testing saw the largest increase resulting in twice as many people diagnosed. Only 23.2% of HBV and 14.9% of HCV‐positive tests were referred to secondary care. In an index practice, the most common flag was a history of STIs (477/719, 66.3%). Individuals with previous or current drug use and those with a known hepatitis contact were more likely to be offered a test compared to those flagged due to a history of STI. HIV and HBV testing was lower in males following a test offer. There was an increased likelihood of testing for HBV and HCV with increasing age. Additionally, individuals with previous or current drug use and individuals with a known hepatitis contact were more likely to test for HCV compared to individuals flagged due to STI history. CIVHIT shows promise to assist with the elimination of BBVs.

  • Investigation of Serum Markers of Hepatic Fibrosis in Equids

    by Julie F.N. Potier, Andy E. Durham, Raakesh Modi, William Rosenberg, Sophie A. Dash


  • Open Access

    A scoping review of media campaign strategies used to reach populations living with or at high risk for Hepatitis C in high income countries to inform future national campaigns in the United Kingdom

    by David Etoori, Monica Desai, Sema Mandal, William Rosenberg, Caroline A Sabin

    With the advent of direct acting antivirals, the World Health Organisation proposed eliminating Hepatitis C as a public health threat by 2030. To achieve this, countries need to diagnose, engage in care and treat their undiagnosed populations. This will require sensitisation campaigns. However previous media campaigns have had mixed impact. We conducted a scoping review to identify and understand the impact of previous Hepatitis C media campaigns. These findings could inform the delivery of future campaigns. We searched five electronic databases for published literature on media campaigns conducted for Hepatitis C awareness, testing, and treatment in Organisation for Economic Co-operation and Development (OECD) countries since 2010. Two independent reviewers screened citations for inclusion. Additionally, we spoke to stakeholders in the Hepatitis C field in the UK and conducted a Google search to identify any unpublished literature. A quantitative synthesis was conducted to identify targeted populations, strategies and media used, aims and impact of the campaigns. A title and year of publication screening of 3815 citations resulted in 113 papers that had a full abstract screen. This left 50 full-text papers, 18 were included of which 9 (50%) were from Europe. 5 (27.8%) of campaigns targeted minority ethnicities, and 9 (50%) aimed to increase testing. A Google search identified 6 grey literature sources. Most campaigns were not evaluated for impact. Discussions with stakeholders identified several barriers to successful campaigns including lack of targeted messaging, stigmatising or accusatory messaging, and short-lived or intermittent campaign strategies. Future campaigns will likely need to be multifaceted and have multiple tailored interventions. Campaigns will need to be sizeable and robust, integrated into health systems and viewed as an ongoing service rather than one-offs.


  • Open Access

    Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys

    by Kushala W M Abeysekera, Ankur Srivastava, Ian Rowe, Helen Jarvis, Stephen D Ryder, Andrew Yeoman, John F Dillon, William Rosenberg

    Introduction: The increasing availability of non-invasive tests (NITs) has created the opportunity to explore their use in improving risk stratification of advanced liver disease. The study aimed to determine the attitudes and practices among UK secondary care specialists, focusing primarily on attitudes to fibrosis assessment and the use of NITs. Methods: Two web-based surveys were circulated, first between 2014 and 2015 (survey 1), and again in 2021 (survey 2). The surveys were promoted via the British Society of Gastroenterology, the British Association for the Study of the Liver and using Twitter. Results: In survey 1, 215 healthcare professionals (HCPs) completed the online survey. 112 HCPs completed survey 2. 71 acute UK trusts were represented in survey 1 compared with 60 trusts in survey 2. Between the two surveys, the proportion of HCPs performing fibrosis assessment in all or nearly all cases rose from 45.1% to 74.1% (χ2=25.01; p2=7.35; p=0.007). Availability of tests has increased but is not universal. The proportion reporting availability as a barrier to uptake fell from 57.2% of responses in survey 1 to 38.4% in 2021 χ2=11.01; p=0.0009). Conclusion: Between 2014 and 2021, the role of NITs in fibrosis assessment has risen substantially, as has the proportion of clinicians using NITs in clinical pathways to assess risk of liver disease. Poor access to NITs remains the predominant barrier.


  • Open Access

    An entropic safety catch controls hepatitis C virus entry and antibody resistance

    by Lenka Stejskal, Mphatso D Kalemera, Charlotte B Lewis, Machaela Palor, Lucas Walker, Tina Daviter, William D Lees, David S Moss, Myrto Kremyda-Vlachou, Zisis Kozlakidis, et al.

    E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion remain unknown. Hypervariable region-1 (HVR-1) of E2 is a putative intrinsically disordered protein tail. Here, we demonstrate that HVR-1 has an autoinhibitory function that suppresses the activity of E1E2 on free virions; this is dependent on its conformational entropy. Thus, HVR-1 is akin to a safety catch that prevents premature triggering of E1E2 activity. Crucially, this mechanism is turned off by host receptor interactions at the cell surface to allow entry. Mutations that reduce conformational entropy in HVR-1, or genetic deletion of HVR-1, turn off the safety catch to generate hyper-reactive HCV that exhibits enhanced virus entry but is thermally unstable and acutely sensitive to neutralising antibodies. Therefore, the HVR-1 safety catch controls the efficiency of virus entry and maintains resistance to neutralising antibodies. This discovery provides an explanation for the ability of HCV to persist in the face of continual immune assault and represents a novel regulatory mechanism that is likely to be found in other viral fusion machinery.


  • Open Access

    The Enhanced Liver Fibrosis test maintains its diagnostic and prognostic performance in alcohol-related liver disease: a cohort study

    by Declan Connoley, Preya Janubhai Patel, Brian Hogan, Sudeep Tanwar, Freya Rhodes, Julie Parkes, Alastair Burt, Jennifer Watkins, William Sievert, William Rosenberg

    Background: Alcohol is the main cause of chronic liver disease. The Enhanced Liver Fibrosis (ELF) test is a serological biomarker for fibrosis staging in chronic liver disease, however its utility in alcohol-related liver disease warrants further validation. We assessed the diagnostic and prognostic performance of ELF in alcohol-related liver disease. Methods: Observational cohort study assessing paired ELF and histology from 786 tertiary care patients with chronic liver disease due to alcohol (n = 81) and non-alcohol aetiologies (n = 705). Prognostic data were available for 64 alcohol patients for a median of 6.4 years. Multiple ELF cut-offs were assessed to determine diagnostic utility in moderate fibrosis and cirrhosis. Survival data were assessed to determine the ability of ELF to predict liver related events and all-cause mortality. Results: ELF identified cirrhosis and moderate fibrosis in alcohol-related liver disease independently of aminotransferase levels with areas under receiver operating characteristic curves of 0.895 (95% CI 0.823–0.968) and 0.923 (95% CI 0.866–0.981) respectively, which were non-inferior to non-alcohol aetiologies. The overall performance of ELF was assessed using the Obuchowski method: in alcohol = 0.934 (95% CI 0.908–0.960); non-alcohol = 0.907 (95% CI 0.895–0.919). Using ELF < 9.8 to exclude and ≧ 10.5 to diagnose cirrhosis, 87.7% of alcohol cases could have avoided biopsy, with sensitivity of 91% and specificity of 85%. A one-unit increase in ELF was associated with a 2.6 (95% CI 1.55–4.31, p < 0.001) fold greater odds of cirrhosis at baseline and 2.0-fold greater risk of a liver related event within 6 years (95% CI 1.39–2.99, p < 0.001). Conclusions: ELF accurately stages liver fibrosis independently of transaminase elevations as a marker of inflammation and has superior prognostic performance to biopsy in alcohol-related liver disease.


  • Open Access

    Is there scope to improve the selection of patients with alcohol-related liver disease for referral to secondary care? A retrospective analysis of primary care referrals to a UK liver centre, incorporating simple blood tests

    by Freya Alison Rhodes, Sara Cococcia, Preya Patel, Jasmina Panovska-Griffiths, Sudeep Tanwar, Rachel H Westbrook, Alison Rodger, William Rosenberg

    Objectives Twenty per cent of people with alcohol use disorders develop advanced fibrosis and warrant referral to secondary care. Improving outcomes in alcohol-related liver disease (ArLD) relies on its earlier detection in primary care with non-invasive tests (NIT). We aimed to determine the proportion of alcohol-related referrals who were diagnosed with advanced fibrosis in secondary care, the prevalence of both alcohol and fatty liver disease (‘BAFLD’) and the potential impact of NIT on referral stratification. Design/setting Retrospective analysis of all general practitioner-referrals with suspected ArLD/non-alcoholic fatty liver disease (NAFLD) to a UK hepatology-centre between January 2015 and January 2018. Participants Of 2944 new referrals, 762 (mean age 55.5±13.53 years) met inclusion criteria: 531 NAFLD and 231 ArLD, of which 147 (64%) could be reclassified as ‘BAFLD’. Primary outcome measure Proportion of referrals with suspected ArLD/NAFLD with advanced fibrosis as assessed by tertiary centre hepatologists using combinations of FibroScan, imaging, examination and blood tests and liver histology, where indicated. Secondary outcome measures Included impact of body mass index/alcohol consumption on the odds of a diagnosis of advanced fibrosis, and performance of NIT in predicting advanced fibrosis in planned post-hoc analysis of referrals. Results Among ArLD referrals 147/229 (64.2%) had no evidence of advanced fibrosis and were judged ‘unnecessary’. Advanced fibrosis was observed in men drinking ≥50 units per week (U/w) (OR 2.74, 95% CI 1.51 to 5, p=0.001) and ≥35 U/w in women (OR 5.11, 95% CI 1.31 to 20.03, p=0.019). Drinking >14 U/w doubled the likelihood of advanced fibrosis in overweight/obesity (OR 2.11; 95% CI 1.44 to 3.09; pConclusions The majority of referrals with suspected ArLD were deemed unnecessary. NIT could improve identification of liver damage in ArLD, BAFLD and NAFLD in primary care. Anecdotal thresholds for harmful drinking (35 U/w in women and 50 U/w in men) were validated. The impact of alcohol on NAFLD highlights the importance of multi-causality in chronic liver disease.


  • Open Access

    Uncovering unsuspected advanced liver fibrosis in patients referred to alcohol nurse specialists using the ELF test

    by Freya Rhodes, Sara Cococcia, Jasmina Panovska-Griffiths, Sudeep Tanwar, Rachel H. Westbrook, Alison Rodger, William M. Rosenberg

    Background and aims: Alcohol use disorders (AUD) cause 7.2% of UK hospital admissions/year. Most are not managed by hepatologists and liver disease may be missed. We used the Enhanced Liver Fibrosis (ELF) test to investigate prevalence and associations of occult advanced liver fibrosis in AUD patients not known to have liver fibrosis. Methods: Liver fibrosis was assessed using ELF in prospective patients referred to the Royal Free Hospital Alcohol Specialist Nurse (November 2018–December 2019). Known cases of liver disease were excluded. Patient demographics, blood tests, imaging data and alcohol histories recorded. Advanced fibrosis was categorised as ELF ≥ 10.5. Results: The study included 99 patients (69% male, mean age 53.1 ± 14.4) with median alcohol intake 140 units/week (IQR 80.9–280), and a mean duration of harmful drinking of 15 years (IQR 10–27.5). The commonest reason for admission was symptomatic alcohol withdrawal (36%). The median ELF score was 9.62, range 6.87–13.78. An ELF score ≥ 10.5 was recorded in 28/99 (29%) patients, of whom 28.6% had normal liver tests. Within previous 5-years, 76% had attended A&E without assessment of liver disease. The ELF score was not associated with recent alcohol intake (p = 0.081), or inflammation (p = 0.574). Conclusion: Over a quarter of patients with AUD had previously undetected advanced liver fibrosis assessed by ELF testing. ELF was not associated with liver inflammation or recent alcohol intake. The majority had recent missed opportunities for investigating liver disease. We recommend clinicians use non-invasive tests to assess liver fibrosis in patients admitted to hospital with AUD.


  • Open Access

    Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis

    by Chetanya Sharma, Sara Cococcia, Nicola Ellis, Julie Parkes, William Rosenberg

    Background and Aims: The rising incidence of chronic liver disease (CLD) has increased the need for early recognition. This systematic review assesses the diagnostic accuracy of the enhanced liver fibrosis (ELF) test in cases of advanced fibrosis and cirrhosis due to multiple etiologies in at‐risk populations.Methods: Studies evaluating the ELF accuracy in identifying advanced fibrosis or cirrhosis, defined as METAVIR stage F ≥ 3 and F = 4 or equivalent, in patients with non‐alcoholic fatty liver disease (NAFLD), alcohol liver disease (ALD), or viral hepatitis were included. Liver biopsy was used as the reference standard. Medline and Embase databases were searched. The QUADAS‐2 tool was used as a framework to assess risk of bias and applicability. The area under the receiver operator curve (AUROC) was extracted as a summary measure of diagnostic accuracy.Results: Thirty‐six studies were included: 11 hepatitis C, 4 hepatitis B, 9 NAFLD, 2 ALD, and 10 mixed. The ELF test showed good diagnostic performance in detecting advanced fibrosis in patients with viral hepatitis (AUROC 0.69 to 0.98) and excellent performance in NAFLD (AUROC 0.78 to 0.97) and ALD (AUROC from 0.92 to 0.94). There is also evidence of good diagnostic performance for detecting cirrhosis in patients with viral hepatitis (AUROC 0.63 to 0.99), good performance in NAFLD (AUROC 0.85 to 0.92), and excellent performance in patients with ALD (AUROC 0.93 to 0.94).Conclusion: This systematic review supports the use of the ELF test across a range of CLD as a possible alternative to liver biopsy in selected cases.